PubMed Health⌕ Search

Biomedical subjects

O Kjellgren

Publications and source records attributed to O Kjellgren.

At least 37 records · Page 2Linked to original sources
PubMed1988

Plasma level of estradiol in patients with ovarian malignant tumors.

Plasma concentration of estradiol has been investigated in women with epithelial ovarian carcinoma. Forty-nine postmenopausal and/or oophorectomized women with no other malignant or endocrine disease were included in the study. All FIGO stages and the histological types IC, IIC, IIIC, and V were represented. Tumor volumes were evaluated once a month using bimanual recto-vaginal palpation under full anesthesia. Blood samples were drawn for estradiol radioimmunoassay at monthly intervals during 3 months. Plasma levels were compared with a control group of postmenopausal women with no internal disease or medication. The results show a significantly higher concentration in patients with large tumor volume compared to postmenopausal controls and a positive relationship between tumor volume, stage, and plasma estradiol level. Histological type seems to be of less importance and secondary to tumor volume. During chemotherapy the plasma concentration of estradiol decreased rapidly with the reduction of tumor volume.

Adult↗
PubMed1986

Androstenedione production by malignant epithelial ovarian tumors.

The concentration of plasma androstenedione in women with malignant epithelial ovarian tumors is investigated. Fifty-one postmenopausal and/or oophorectomized women with no other malignant or endocrine disease are included in the study. All FIGO stages and the histologic types I C, II C, III C, and IV are represented. The tumor volumes were evaluated once a month using bimanual rectovaginal palpation under anesthesia. Four blood samples were drawn for androstenedione radioimmunoassay at monthly intervals. The plasma levels were compared with those of a control group of postmenopausal women and a control group of fertile women in the follicular phase of the menstrual cycle. The results show a relationship between tumor volume and plasma androstenedione level. Histologic type and FIGO stage seem to be of subordinate importance and secondary to tumor volume. During chemotherapy the plasma concentration of androstenedione decreased parallel to the reduction in tumor volume. The initial plasma androstenedione concentration seems to have prognostic importance.

Adult↗
PubMed1986

Plasma progesterone and androstenedione in relation to changes in tumor volume and recurrence in women with ovarian carcinoma.

The concentrations of plasma progesterone and androstenedione were investigated in 13 postmenopausal women with malignant ovarian tumors who showed no signs of other malignant or endocrine disease. FIGO stages III and IV were represented and histological types were mainly Ic and V. Tumor volumes were generally evaluated once a month using bimanual rectovaginal palpation under anesthesia. Blood samples were drawn for progesterone and androstenedione radioimmunoassay at every admittance to hospital. In 12 of the 13 patients the plasma levels of progesterone and in 10 the plasma levels of androstenedione decreased in parallel with the reduction in tumor volume and increased again when recurrence occurred. The plasma levels at diagnosis of recurrence of tumor and the levels when the largest tumor volume was demonstrated were compared to the preceding values and found to be significantly higher. In order to evaluate if progesterone or androstenedione could predict recurrence of tumor, plasma levels at certain intervals before recurrence were compared to the preceding value. Significant rise was considered to have occurred when plasma concentration had risen to twice the coefficient of variation of the assay above the previous value and continued to rise. Plasma progesterone indicated recurrence of tumor in 8 cases at least 1 month before recurrence was palpable. Plasma concentration of androstenedione was found to be useful in predicting recurrence in 5 cases 1 month or more before recurrence was palpable. A group of postmenopausal women with disseminated malignant disease of nongenital type was compared to the control groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1986

Testosterone, SHBG and albumin in patients with ovarian carcinoma.

Plasma testosterone, unbound testosterone, Sex Hormone Binding Globulin (SHBG) and albumin were studied in women with 'non-endocrine' ovarian carcinoma prior to and during chemotherapy. Fifty-one postmenopausal or oophorectomized women with cancer of the ovary were studied. The histologic types were IC, IIC, IIIC, V and FIGO stages I-IV. Tumor volumes were evaluated once a month using bimanual recto-vaginal palpation under anesthesia. Blood samples were drawn for testosterone radio-immunoassay, SHBG and albumin analysis on four occasions at monthly intervals. Plasma levels were compared with a control group of postmenopausal women, a control group of fertile women in the follicular phase of the menstrual cycle, and finally a control group of postmenopausal women with non-gynecologic disseminated malignant disease. Testosterone concentrations were found to be higher in women with carcinoma of the ovary than in postmenopausal controls and showed a relationship to tumor volume. Histologic type and FIGO stage were found to be less closely related to plasma testosterone concentration. No significant change was found in the unbound testosterone fraction. SHBG concentrations were elevated in the Large-tumor group. Albumin concentrations were decreased in the Large-tumor group, advanced tumor stage group and in the control group with non-gynecologic disseminated malignant disease.

Adult↗
PubMed1985

Functional cyst or ovarian cancer: histopathological findings during 1 year of surgery.

The histopathological findings recorded during 1 year in 101 women undergoing surgery for palpable ovarian tumors were analyzed with respect to patient age, medical history and presenting symptoms. Almost half of the women (43%) were younger than 30 years and functional cysts or normal ovaries were found in 66 out of totally 101 women. During the following 2 years 18 of these women were subjected to further gynecological surgery and 17 women were infertile. While surgical treatment of functional cysts in young women may be deleterious, 3 cases of ovarian cancer illustrate the diagnostic difficulties and the potential risk of neglecting surgery.

Adolescent↗
PubMed1985

Plasma 20 alpha-OH-progesterone in women with malignant epithelial 'non-endocrine' ovarian tumors.

The production of 20 alpha-OH-progesterone (20 alpha-OH-P) in women with malignant epithelial ovarian tumors was investigated. The study material comprised 51 postmenopausal and/or oophorectomized women with ovarian carcinoma, including the histological types Ic, IIc, IIIc and V and FIGO stages I-IV. Their tumor volumes were evaluated once a month using bimanual recto-vaginal palpation under anesthesia. Blood samples were drawn for 20 alpha-OH-P radio-immunoassay at monthly intervals for 3 months. The plasma levels were compared with those of a control group of postmenopausal women. The results show a relationship between tumor volume and plasma 20 alpha-OH-P level. Another finding is that endometrioid ovarian cancer (histologically IIIc) showed a significantly lower 20 alpha-OH-P production than the other types. The reason for this is discussed.

20-alpha-Dihydroprogesterone↗
PubMed1984

The development of gynecological oncology in Scandinavia during the last 50 years.

The last 50 years of development in gynecological oncology has changed the methods for the diagnosis of cancer and for treatment of cancer, both to give better treatment results. From the beginning the gynecologist could only inspect or palpate. Later on roentgen examination was introduced and later still microscopic diagnosis, more advanced diagnostic methods, e.g. endoscopy, ultrasound, isotope examination and advanced microscopic diagnosis and computerized tomography. Today we are waiting for the break-through in computerized tomography using nuclear spin resonance for the study of tumors and the spread of tumors. Parallel with the development in diagnosis, treatment has developed. Originally surgery was the only method available. Later on low energy radiation, endocrine therapy, chemotherapy and then high voltage energy treatment became available along with some experimental therapies. Today we have a broad range of therapeutic tools to use. In the future we might use prophylaxis more than we do today to prevent cancer and when cancer is present we might enhance the immune defense or introduce specific immuno-therapy with clonal antibodies, specially made for the actual tumor, and surgery, radiotherapy and chemotherapy will be used less.

Female↗
PubMed1983

Progesterone as a possible tumor marker for "nonendocrine" ovarian malignant tumors.

Fifty-one postmenopausal or oophorectomized women with cancer of the ovary were studied. The histologic types were IC, IIC, IIIC, V, and FIGO Stages I-IV. Their tumor volumes were evaluated once a month using bimanual recto-vaginal palpation under anesthesia. Blood samples were drawn for progesterone radioimmunoassay at monthly intervals for 4 months. The plasma levels were compared with those of a control group of postmenopausal women and a control group of fertile women in the follicular phase of the menstrual cycle. The results show a relationship between tumor volume and plasma progesterone level. Histologic type and FIGO stage seem to be less important. During chemotherapy the plasma progesterone value decreased with the reduction in tumor volume. Women bilaterally oophorectomized and radically operated showed a lower plasma progesterone level than both the control groups, which indicates significant progesterone production in the postmenopausal ovary. The results suggest that progesterone may be used as a tumor marker in "nonendocrine" ovarian tumors.

Adult↗